- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05882513
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
A Prospective, Single-arm, Single-center, Exploratory Study of the Safety and Efficacy of Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ming Wu
- Phone Number: +8613757118715
- Email: iwuming22@zju.edu.cn
Study Locations
-
-
-
Hangzhou, China, 310009
- Recruiting
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University
-
Contact:
- Ming Wu, M.D
- Phone Number: +8613757118715
- Email: iwuming22@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- signed informed consent;
- patients age 18 to 75 years old
- primary resectable, histologically confirmed non small cell lung cancer;
- non small cell lung cancer the clinical stage was IIA-IIIB (no N3 patient) (according to AJCC TNM stage, 8th edition).
- ECOG PS 0-1.
- the diseases could be resectable assessed by thoracic oncologist
Exclusion Criteria:
- with significant cardiovascular disease;
- current treatment with anti-viral therapy or HBV;
- Female patients who are pregnant or lactating;
- history of malignancy within 5 years prior to screening;
- active or history of autoimmune disease or immune deficiency;
- signs of distant metastases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lung cancer group
Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1. Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1. Preoperative neoadjuvant therapy for 2-4 cycles, one cycle every 21 days. Surgical resection of lung cancer will be arranged about 4-8 weeks after the last cycle of neoadjuvant therapy. |
Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1. Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1.
Other Names:
radical resection of lung cancer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Response (PCR)
Time Frame: 1 month after surgery
|
No residual invasive tumor cells were found in the pathological examination of resected specimens.
|
1 month after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Pathological Response (MPR)
Time Frame: 1 month after surgery
|
In the pathological examination of resected specimens, the proportion of residual tumor cells was less than 10%.
|
1 month after surgery
|
Objective Response Rate (ORR)
Time Frame: before surgery
|
The proportion of subjects with imaging PR or CR assessed according to RECIST 1.1 criteria
|
before surgery
|
2-year and 5-year overall survival
Time Frame: 2-year and 5-year after surgery
|
The proportion of all study cases in which no death from any cause occurred within 2 years and 5 years after surgery
|
2-year and 5-year after surgery
|
Incidence of Treatment-related Adverse Events
Time Frame: 1 month after surgery
|
Incidence of Treatment-related Adverse Events as Assessed by CTCAE v5.0
|
1 month after surgery
|
R0 resection rate
Time Frame: 1 month after surgery
|
The pathological results will showed that the incision margin was negative and no residual cancer cells were found under the microscope
|
1 month after surgery
|
Collaborators and Investigators
Investigators
- Study Chair: Weilin Wang, 2nd Affiliated Hospital, School of Medicine, Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-0485
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on Serplulimab and neoadjuvant therapy
-
Sichuan Cancer Hospital and Research InstituteRecruiting
-
Beijing Shijitan Hospital, Capital Medical UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Acıbadem Atunizade HospitalCompletedNeoadjuvant ChemotherapyTurkey
-
Second Affiliated Hospital, School of Medicine,...RecruitingNeoadjuvant Therapy | Esophageal Squamous Cell CarcinomaChina
-
Centre Georges Francois LeclercRecruiting
-
Grupo Espanol Multidisciplinario del Cancer DigestivoRecruitingPatients With Locally Advanced Rectal CancerSpain
-
Duke UniversityUniversity of North Carolina, Chapel HillRecruiting
-
Center of Personalized Medicine, PirogovaI.M. Sechenov First Moscow State Medical University; Center for New Medical...UnknownBreast Cancer-specific SurvivalRussian Federation